Phenotypic Assays and Sequencing Are Less Sensitive Than Point Mutation Assays for Detection of Resistance in Mixed HIV-1 Genotypic Populations
- 1 October 1999
- journal article
- basic science
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 22 (2) , 107
- https://doi.org/10.1097/00042560-199910010-00001
Abstract
Summary: The sensitivity and discriminatory power of the 151 and 215 amplification refractory mutation system (ARMS) were evaluated, and their performance for the detection of drug resistance in mixed genotypic populations of the reverse transcription (RT) gene of HIV-1 were compared with T7 sequencing, cycle sequencing, the line probe assay (LiPA) HIV-1 RT test, and the recombinant virus assay (RVA). ARMS and the LiPA HIV-1 RT test were shown to be able to detect minor variants that in particular cases comprised only 1%. T7 sequencing on an ALF semiautomated sequencer could correctly score mixtures only when variants were present at 50%. Cycle sequencing on an ABI PRISM 310 improved the sensitivity for mixtures to about 25%. Using RVA, it was shown that at least 50% of the virus population needed to carry the resistance mutation at codon 184 to afford phenotypic resistance against lamivudine. The two point mutation assays therefore proved to be more sensitive methods than sequencing and RVA to reliably determine a gradual shift in HIV-1 drug resistance mutations in follow-up of patients infected with HIV-1. In 4 of 5 treated patients who were followed by ARMS, a gradual shift in resistant genotypic populations was observed during a period of 6 to 19 months. For 1 patient, a shift from wild to mutant type at position 151 occurred within 2 months, without mixed genotypic intermediate type's being detected.Keywords
This publication has 19 references indexed in Scilit:
- Managing Resistance to Anti-HIV DrugsDrugs, 1999
- Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countriesAIDS, 1998
- Quantitation of Target Molecules from Polymerase Chain Reaction-Based Limiting Dilution AssaysAIDS Research and Human Retroviruses, 1997
- Multiple Drug Resistance to Nucleoside Analogues and Nonnucleoside Reverse Transcriptase Inhibitors in an Efficiently Replicating Human Immunodeficiency Virus Type 1 Patient StrainThe Journal of Infectious Diseases, 1996
- Combination Therapy with Zidovudine and Didanosine Selects for Drug-Resistant Human Immunodeficiency Virus Type 1 Strains with Unique Patterns of pol Gene MutationsThe Journal of Infectious Diseases, 1994
- Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistanceJournal of General Virology, 1994
- Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study.Proceedings of the National Academy of Sciences, 1993
- Ordered Appearance of Zidovudine Resistance Mutations during Treatment of 18 Human Immunodeficiency Virus-Positive SubjectsThe Journal of Infectious Diseases, 1992
- Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytesAIDS, 1991
- Multiple Mutations in HIV-1 Reverse Transcriptase Confer High-Level Resistance to Zidovudine (AZT)Science, 1989